YOLFTbeta
MetaVia Inc.

MetaVia Inc.

MTVA · NASDAQ · Healthcare / Biotechnology

1.30USD+0.00 (0.00%)

Price History

Full chart

Market Stats

Previous Close1.30
Open1.43
Day Range1.25 – 1.43
52-Week Range0.966 – 14.85
Volume49.17K
Market Cap11.00M
P/E (TTM)0.00
Forward P/E0.00
EPS-2.47
Dividend Yield0.00%
Beta0.94
50-Day Avg1.58
200-Day Avg2.54

About

MetaVia Inc., a clinical-stage biotechnology company, focuses on developing novel pharmaceuticals to treat cardiometabolic diseases. The company develops DA-1241, a novel G-Protein-Coupled Receptor 119 agonist with development optionality as a standalone and/or combination therapy that is in Phase 2a clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis, as well as completed Phase 1 clinical trial for the treatment of type 2 diabetes mellitus; and DA-1726, a novel oxyntomodulin analogue functioning as a GLP-1 receptor and glucagon receptor dual agonist, which is in Phase 1 trial for the treatment of obesity. Its therapeutic programs include ANA001, a proprietary oral niclosamide formulation for the treatment of patients with moderate COVID-19; NB-01 for the treatment of painful diabetic neuropathy; NB-02 for the treatment of cognitive impairment; and Gemcabene for the treatment of dyslipidemia. The company has a license agreement with Pfizer Inc. for the research, development, manufacture, and commercialization of Gemcabene; and Dong-A ST, a sole manufacturer for the production of DA-1241 and DA-1726. The company was formerly known as NeuroBo Pharmaceuticals, Inc. and changed its name to MetaVia Inc. in November 2024. MetaVia Inc. is headquartered in Cambridge, Massachusetts.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEOMr. Hyung Heon Kim
  • Employees8
  • Headquarters545 Concord Avenue, Cambridge, MA, United States, 02138, USA
  • Websitehttps://www.metaviatx.com

Leadership

  • Mr. Hyung Heon KimCEO, President & Director · b. 1977
  • Mr. Marshall H. WoodworthChief Financial Officer · b. 1958
  • Dr. Mi-Kyung KimChief Scientific Officer
  • Mr. Robert HomolkaSenior Vice President of Clinical Operations
  • Dr. W. Christopher Fang M.D.Consulting Chief Medical Officer & Advisor
  • Mr. Michael C. PineSenior Vice President of Business Development Advisor · b. 1977

Financials

Income Statement

Currency: USD2014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue------000000
Cost of Revenue------67.00K72.00K28.00K7.00K24.00K19.00K
Gross Profit-------67.00K-72.00K-28.00K-7.00K-24.00K-19.00K
Operating Expense------29.65M15.23M19.60M15.88M28.79M13.69M
Operating Income-266.00K-8.08M-14.70M-33.12M-15.49M-20.18M-29.72M-15.30M-19.63M-15.89M-28.81M-13.71M
EBITDA-266.00K-7.17M-14.70M-33.12M-15.49M-20.16M-29.67M-15.24M-11.76M-12.46M-27.57M-12.95M
Net Income-320.00K-9.03M-14.59M-33.41M-15.53M-21.31M-29.68M-15.28M-13.97M-12.47M-27.59M-12.97M
R&D52.00K3.99M8.74M22.69M13.88M17.48M21.87M6.55M2.78M9.16M21.53M6.80M
Interest Expense55.00K762.00K-286.00K40.00K22.00K-02.19M0--

Balance Sheet

Currency: USD2014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets348.00K4.49M24.75M19.02M3.82M14.47M10.97M16.80M33.53M22.78M16.26M69.12M
Total Liabilities879.00K16.87M4.12M15.08M17.11M2.18M3.77M2.20M11.78M6.10M8.33M63.79M
Total Equity-531.00K-12.38M20.63M3.94M-13.29M12.29M7.20M14.60M21.75M16.68M7.93M5.33M
Cash317.00K3.62M24.03M18.47M2.85M13.91M10.09M16.39M33.36M22.43M16.02M10.28M
Total Debt737.00K6.42M-10.04M9.58M116.00K94.00K71.00K-203.00K136.00K210.00K
Net Debt420.00K2.80M-24.03M-8.44M6.73M-13.79M-9.99M-16.32M-33.36M-22.23M-15.88M-10.07M

Cash Flow

Currency: USD2014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow-195.00K-5.43M-11.04M-26.90M-14.45M-7.04M-10.76M-15.13M-11.71M-10.80M-24.71M-15.70M
Investing Cash Flow-----3.00K-6.06M69.00K-586.00K8.00K-50.00K-8.00K-2.00K
Financing Cash Flow509.00K8.74M31.46M21.34M17.25M24.17M6.86M22.03M28.68M-80.00K18.30M9.96M
Capital Expenditure00003.00K214.00K4.00K3.00K050.00K8.00K2.00K
Free Cash Flow-195.00K-5.43M-11.04M-26.90M-14.45M-7.25M-10.77M-15.14M-11.71M-10.85M-24.72M-15.70M
FCF to OCF100.00%100.00%100.00%100.00%100.02%103.04%100.04%100.02%100.00%100.46%100.03%100.01%

Earnings

Report DateAug 31, 2016Nov 2, 2016Mar 16, 2017May 9, 2017Sep 13, 2017Nov 15, 2017Mar 15, 2018May 8, 2018Aug 13, 2018Nov 8, 2018Mar 15, 2019May 6, 2019Aug 9, 2019Dec 27, 2019Mar 30, 2020May 20, 2020Aug 11, 2020Nov 13, 2020Apr 15, 2021Aug 16, 2021Nov 15, 2021May 25, 2022Aug 16, 2022Nov 14, 2022Mar 30, 2023May 12, 2023Aug 9, 2023Nov 13, 2023Mar 28, 2024May 9, 2024Aug 14, 2024Nov 7, 2024Mar 20, 2025May 14, 2025Aug 7, 2025Nov 6, 2025Dec 31, 2025May 14, 2026Aug 6, 2026Nov 5, 2026
EPS Estimate-----22.00-17.05-0.69-0.67-0.55-0.47-0.41-0.42-0.12-0.11-2.25-264.00-712.80-448.80-501.60-396.00-475.20-0.16-5.10-448.80-1.20-55.44-11.44-9.68-8.63-3.63-12.36-8.03-8.14-0.30-0.32-2.75-1.82-0.75-0.85-0.94
EPS Actual-2549.34-3389.34-4672.28-4723.76-0.75-0.63-0.63-14.50-11.75-10.75-6.50-6.75-5.00-6.00-0.73-792.00-396.00-501.60-3168.00-475.20-422.40-0.17-0.12-308.004.93-5.28-1.76-7.92-25.08-1.32-20.35-6.05-3.52-0.36-0.26-1.54--0.79-0.90-
Surprise----96.59%96.31%8.70%-2064.18%-2036.36%-2187.23%-1485.37%-1507.14%-4066.67%-5354.55%67.56%-200.00%44.44%-11.76%-531.58%-20.00%11.11%-6.25%97.65%31.37%510.83%90.48%84.62%18.18%-190.61%63.64%-64.64%24.66%56.76%-20.00%18.75%44.00%--5.33%-5.88%-
Timing---------------After-hoursAfter-hoursAfter-hoursAfter-hoursPre-marketPre-market--After-hours-After-hoursAfter-hoursAfter-hoursAfter-hours-Pre-marketPre-marketPre-market-Pre-marketPre-market-After-hoursAfter-hours-

Key Statistics & Ratios

Market Cap11.00M
Enterprise Value-1.69M
Trailing P/E0.00
Forward P/E0.00
Price / Sales0.00
Price / Book1.58
EPS-2.47
Book Value1.04
Revenue (TTM)0
Gross Profit (TTM)0
EBITDA-14.91M
Profit Margin0.00%
Operating Margin0.00%
Return on Equity-175.68%
Return on Assets-58.82%
Shares Outstanding6.59M
Shares Float4.80M
Beta0.94
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Analyst Ratings

Strong Buy
Based on 2 analystsTarget 19.33
  • Strong Buy
    1
  • Buy
    1

Ownership Breakdown

Institutions
13.87%
Insiders
28.61%
Retail / Other
57.52%

Top Institutional Holders

  • Citadel Advisors Llc
    61.21K0.93%
  • Geode Capital Management, LLC
    33.63K0.51%
  • Jane Street Group LLC
    10.90K0.17%
  • Aries Wealth Management
    10.00K0.15%
  • Vanguard Fiduciary Trust Co
    6.94K0.11%
  • Tower Research Capital LLC
    2.60K0.04%
  • Vanguard Capital Management, LLC
    2.22K0.03%
  • BlackRock Inc
    4790.01%
  • SBI Securities Co Ltd
    2050.00%
  • Brown Brothers Harriman & Co
    20.00%
  • Danske Bank A/S.
    20.00%
  • UBS Group AG
    10.00%
  • Morgan Stanley - Brokerage Accounts
    00.00%
  • JPMorgan Chase & Co
    00.00%
  • Bank of America Corp
    00.00%
  • Caitong International Asset Management Co., Limited.
    30.00%
  • International Assets Investment Management, LLC
    20.00%

Top Fund Holders

  • Fidelity Extended Market Index
    20.35K0.31%
  • Fidelity Total Market Index
    4310.01%
  • Vanguard U.S. Eq Idx £ Acc
    1840.00%

Stock Splits

  • Dec 5, 20251:11
  • Dec 21, 20231:8
  • Sep 13, 20221:30
  • Dec 31, 20191:25